Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Leading Kansas Cardiologist calls for Congressional investigation into questionable Justice Department allegations regarding nation's leading life-saving heart procedure based on faulty scientific review and bad legal precedents


News provided by

Dr. Joseph P. Galichia

Jun 10, 2019, 08:35 ET

Share this article

Share toX

Share this article

Share toX

WICHITA, Kan., June 10, 2019 /PRNewswire/ -- In a letter sent to former patients and friends, Dr. Joseph P. Galichia, MD, FACC, said today, "This past week, the details of a settlement I reached with the Department of Justice after seven years of negotiations were made public. The DOJ press announcement received considerable media attention, much of which was factually inaccurate, out of context and therefore potentially damaging to patients and my colleagues."

Dr. Galichia, a former two term president of the International Society of Cardiovascular Interventionists and former founder of the Galichia Medical Group and founder of the Galichia Heart Hospital, announced today that he is calling on Congress to investigate "the DOJ's flawed probe, according to board certified experts based on a whistleblower's civil action and the effect that questionable legal precedents are having on cardiologists nationwide." Dr. Galichia said that the so-called whistleblower was a disgruntled former employee who started the entire action and is not even a cardiologist.

Dr. Galichia stated, "Unfortunately, the federal government has chosen to solve its financial problems with Medicare by pursuing physicians, hospitals, and other healthcare providers to seek reimbursement of money paid for legitimate patient care. This national trend of accusing providers seriously interferes with the patient-physician relationship and leaves many patients without the care they need because physicians and other providers are intimidated by the risk of a fraud allegation by the federal government."

This week Dr. Galichia agreed to a $5.8 million settlement with the government rather than prolong an already seven year-long investigation which, he said, had flawed results, according to a number of highly qualified expert physicians in cardiology regarding the use of a life-saving procedure of which he was one of the pioneers in the U.S., known as balloon angioplasty with stent procedure. This procedure has been credited, in large part, with the reduction in mortality due to heart disease, the nation's leading fatal disease.

"The federal government decides, after the fact, what care the patient should have received, second-guessing the physician and the patient regardless of the health or satisfaction of the patient," Dr. Galichia explained. "We know that the care we have provided to our patients is precisely the care they needed. Expert interventional cardiologists who reviewed the 100 cases in this investigation unanimously agreed that our treatment was appropriate."

Gary Ayers, counsel for Dr. Galichia, explained, "The federal government has compounded the problem by incentivizing disgruntled whistleblowers and their lawyers to make false allegations, which the federal government then uses to extract large settlements from the providers. The government pays a physician 'expert' to second-guess another physician's medical judgment, then alleges this supposed disagreement over treatment is fraud. In Dr. Galichia's case, the government's 'expert opinion' was absolutely wrong according to four independent, board-certified interventional cardiologists who reviewed the same cases. The government's 'expert opinion' was also wrong according to the patients who received Dr. Galichia's care. Hundreds if not thousands of providers across the country have experienced this same phenomenon. Congress needs to reign in the federal government's overreaching and abusive behavior, because it puts patients at risk of not receiving the medical care they need and deserve."

Dr. Galichia and his legal team have cooperated fully with DOJ investigators over the past seven years but, he said, "The entire investigation simply involved too much time and expense to adequately and scientifically evaluate the substance." Dr. Galichia summed up the allegations and the probe by the DOJ as, "…the government's baseless and relentless pursuit, plus the evolving federal court system which has made it all but impossible for expert physicians and cardiologists to counter a single expert witness paid by the federal government. Their expert is a full-time professor rather than a full-time interventional cardiologist. Critical records used in patient procedures were lost and their so-called evidence is without scientific foundation. Unfortunately, because of unrealistic legal precedents, going to court is no longer an option for innocent cardiologists across America, who are just trying to save lives."

Excerpts from Dr. Galichia's letter:

  • [Dr. Galichia] firmly denies the allegations made by the "whistleblower" and his attorney in the action just settled in the agreement with the justice department and related media coverage.
  • [Dr. Galichia] agreed to the settlement only because, after seven years of cooperating with the investigation, the action was taking up far too much of [his] time and energy. Further, it simply became too costly to keep defending against these false accusations. 
  • In disputing the allegations of this case, [Dr. Galichia] engaged four cardiology experts to review the cases rejected by the Government's expert. Each of the four experts holds multiple board certifications, are practicing cardiology interventionalists and have each spent time as professors at one or more medical schools. They all serve or have served as directors of their practices and their hospital's cardiology departments, conducting peer review of catheterizations for their medical staffs. They are all respected experts locally, nationally and internationally. These experts concluded that in all of the cases in question, additional review the experts determined that Dr. Galichia's treatments were medically appropriate.
  • OF NOTE: At least twelve of the interventions rejected by the government's expert were confirmed by intravascular ultrasound ("IVUS"). Though the hospital where they were performed could not locate the crucial IVUS film for each of the cases, the hospital did produce IVUS film for five of the interventions rejected by the government expert. In each of those cases, the objective IVUS evidence established that the treated lesion was significant, and it was medically necessary to treat it.
  • Settling this case is not an admission of any liability by Dr. Galichia or by his former practice, Galichia Medical Group, GMED.
  • Dr. Galichia has devoted his entire career to the practice of medicine and the cardiovascular care of many thousands of Americans and patients from around the world.
  • Dr. Galichia feels that, in his words, "this case has been a matter of legal bullying, based on hearsay from a former GMED employee who is disgruntled over his abrupt release from his employment."
  • According to Dr. Galichia, "It is my understanding that the whistleblower will receive $1.16 million from the settlement and that he is sharing a considerable percentage of it with the attorney who represented him."

During the seven years of diligent negotiations by and on behalf of Dr. Galichia, two federal appellate courts ruled that cardiologists cannot reasonably disagree by more than 10% to 20% about the extent of blockage in an artery. "A precedent had been set, but it was a legal precedent, not a medical one: If a government doctor says an artery is 30% blocked, any doctor who says it's more than 70% blocked must be lying," according to Kyle Clark and Andrew George in the Wall Street Journal, December 28, 2018.*

* "A Second Opinion Becomes a Guilty Verdict," https://www.wsj.com/articles/a-second-opinion-becomes-a-guilty-verdict-11545955656.

For more information, contact:

Stephen Jaffe, Jaffe & Company Public Relations
9663 Santa Monica Blvd, Suite 633, Beverly Hills, CA 90210, Telephone: 1.310.275.7327, cell: (310) 713-4849, E-mail: [email protected],

Maggie Chamberlin Holben, APR, Absolutely Public Relations
3343 S. Nelson Court, Lakewood, CO 80227, Telephone: 1.303.669.3558
[email protected]

SOURCE Dr. Joseph P. Galichia

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.